There are innumerable intricacies to the development of cancer, including breast cancer which is the second leading cause of cancer death for women.
One protein known as HER2, which can cause a more aggressive cancer, has already been a target for research and treatment in breast cancer. Now a different target — another protein, HER3 — is emerging as a potential crucial biomarker in some of these cases.
And Joan Garrett, PhD, assistant professor of pharmaceutical sciences at the University of Cincinnati's James L. Winkle College of Pharmacy, hopes to learn more about HER3 and its role in breast cancer development.
“Our research is focused on understanding if mutations of a protein called HER3 are involved in causing breast cancers,” says Garrett, who is also a member of the UC Cancer Center.
Garrett recently received a $792,000 Research Scholar Grant from the American Cancer Society for this work.